Applied Therapeutics Inc. experienced a significant decline in stock value, plummeting 74.5% following the U.S. Food and Drug Administration's (FDA) decision to reject its drug Govorestat, intended for the treatment of galactosemia. In response to this setback, RBC has downgraded the company's stock rating from 'outperform' to 'sector perform' and adjusted its target price from $12 to $4. Similarly, Baird has reduced its target price for Applied Therapeutics from $14 to $5. In contrast, Citigroup has raised its target price for Autodesk Inc. from $358 to $361 and for Ulta Beauty Inc. from $345 to $390. Additionally, Citigroup significantly increased its target price for CrowdStrike Holdings Inc. from $300 to $400. Barclays has also lowered its target price for Brown & Brown Inc. from $53 to $49. This week marks a busy earnings schedule, with companies such as Salesforce, Okta, and Lulu Lemon set to report their results.